Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, Catherine Boccaccio, Cécile Deal, Marie-Odile Petillon, Olivier Allangba, Philippe Agape, Pierre Arnautou, Rakiba Belkhir, Sylvie Cailleres, Driss Chaoui, Marie-Lorraine Chrétien, Olivier Decaux, Samantha Schulmann, Laurent Frenzel, Lauris Gastaud, Antoine Huart, Cyrille Hulin, Lionel Karlin, Kamel Laribi, Ronan Le Calloch, Pascal Lenain, Margaret Macro, Salomon Manier, Lydia Montes, Stéphane Moreau, Philippe Moreau, Véronique Morel, James Norwood, Frédérique Orsini Piocelle, Aurore Perrot, Gian Matteo Pica, Philippe Rey, Anna Schmitt, Anne-Marie Stoppa, Mourad Tiab, Cyrille Touzeau, Valérie Vidal, Marguerite Vignon, Laure Vincent, Zoé Van De Wyngaert, Charles Zarnitsky, Naima Kerbouche, Prani Paka, Xavier Leleu, Bertrand Arnulf, Hervé Avet-Loiseau
Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety in real-world of BM in patients who benefited from an early access program. We conducted an observational, retrospective, multicenter study. Eligibility criteria were treatment of relapsed or refractory multiple myeloma (RRMM) in monotherapy in adult patients who have received at least 3 lines of therapy previously, including at least one immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody, and whose disease progressed during the last treatment period...
April 20, 2023: Haematologica